Navigation Links
OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
Date:5/30/2009

others, the possibility that any benefit in patient survival will not be maintained or will become less substantial as patient survival follow up continues, risks that clinical trials will not be successful or confirm earlier clinical trial results, including the risk that the survival benefit will not be confirmed by a Phase 3 clinical trial, risks associated with obtaining funding from third parties or completing a financing necessary to support the costs and expenses of a Phase 3 clinical trial, the timing and costs of clinical trials and regulatory approvals will be different than management currently anticipates, risks relating to the development, safety and efficacy of therapeutic drugs and potential applications for these products and the risk factors set forth in the Company's filings with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for fiscal year 2008. The Company undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof.


'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
2. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
3. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
4. OncoGenex Reports First Quarter Financial Results
5. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
6. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
7. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
8. OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
9. OncoGenex Pharmaceuticals to Webcast Financial Results for Fourth Quarter and Fiscal Year 2008 and Provide Outlook for 2009
10. OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer
11. OncoGenex To Present At The RBC Capital Markets 2008 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Biofertilizers stimulate microbial activities in soil. These microorganisms generate ... activities in the soil or in the rhizosphere. The ... on reducing environmental pollution and on reducing the usage ... the bio fertilizers market with analysis and forecasting of ...
(Date:1/22/2015)... 2015 Eckert & Ziegler Vitalea Science ... services to the pharmaceutical and biotech industry, has announced ... in the position of Director of Science & Technology. ... valuable experience in drug metabolism and bioanalysis to EZVS ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 GEA Niro ... table top laboratory homogenizer, the PandaPLUS 2000, which is ... nanoemulsions , and cell disruption . This compact ... products, fruit juices, liquid food, food additives and ingredients ...
(Date:1/22/2015)... laboratory information management systems market is a rapidly growing ... due to factors such as rising pressure to comply ... and increasing government support for adoption of HCIT solutions ... the market focus on technological advancements to further the ...
Breaking Biology Technology:Biofertilizers Market Expected to Reach $1,649.7 Million by 2019 - New Report By MarketsandMarkets 2Biofertilizers Market Expected to Reach $1,649.7 Million by 2019 - New Report By MarketsandMarkets 3Biofertilizers Market Expected to Reach $1,649.7 Million by 2019 - New Report By MarketsandMarkets 4Eckert & Ziegler Vitalea Science appoints Mark Seymour, PhD as Director of Science & Technology 2Eckert & Ziegler Vitalea Science appoints Mark Seymour, PhD as Director of Science & Technology 3GEA Niro Soavi Announces the PandaPLUS 2000 Homogenizer for Processing New Applications for Nanoemulsions and Cell Disruption 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 3Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 4
... 29 Medarex, Inc. (Nasdaq: MEDX ) ... webcast at 8:30 a.m. Eastern Time on Thursday, April ... results for the first quarter of 2009.To access the ... The webcast can be accessed through the Investor Relations ...
... - Updated Survival and Biomarker Data for Ipilimumab to ... (Nasdaq: MEDX ) announced today that the ... cancer, as well as for an anti-PD-1 antibody for ... of presentations at the Annual Meeting of the American ...
... Md., April 29 Vanda Pharmaceuticals Inc. (Nasdaq: ... development and commercialization of clinical-stage product candidates for central ... for the first quarter ended March 31, 2009. ... the first quarter of 2009, compared to $7.5 million ...
Cached Biology Technology:Medarex to Host Business and Financial Update Conference Call on Thursday, April 30, 2009 2Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology 2Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology 3Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology 4Vanda Pharmaceuticals Reports First Quarter 2009 Results 2Vanda Pharmaceuticals Reports First Quarter 2009 Results 3Vanda Pharmaceuticals Reports First Quarter 2009 Results 4Vanda Pharmaceuticals Reports First Quarter 2009 Results 5Vanda Pharmaceuticals Reports First Quarter 2009 Results 6Vanda Pharmaceuticals Reports First Quarter 2009 Results 7Vanda Pharmaceuticals Reports First Quarter 2009 Results 8Vanda Pharmaceuticals Reports First Quarter 2009 Results 9Vanda Pharmaceuticals Reports First Quarter 2009 Results 10
(Date:1/22/2015)... , Jan. 13, 2015 /PRNewswire/ - Today, FindBiometrics, the leading ... the launch of its new website design. "When ... its infancy", says Peter O,Neill , founder and CEO ... the industry needs involvement from the key players on a ...
(Date:1/22/2015)... Conn. , Jan. 20, 2015 NXT-ID, Inc. (NASDAQ: ... mobile commerce market, reports on the recent success of the Wocket™ smart ... Wocket smart wallet was named as one of the "11 ... the "5 Best Products Launched At CES So Far" by Newseveryday.com and ...
(Date:1/22/2015)... Jan. 22, 2015   EyeLock, Inc. , a market leader ... Steve Gerber to the new role of Senior ... for leading development of mobile platforms and wearable solutions for ... and innovation in the semiconductor industry to his role at ...
Breaking Biology News(10 mins):Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2
... Along with pollutants from Asia, transpacific dust plumes deliver ... a manuscript published online ahead of print in the ... "We detected thousands of unique microbial species, many of ... author David J. Smith, a graduate student at the ...
... and climate warming could be creating the right conditions for ... a new Cornell University computer model., The model predicts that ... spread by the invasive Asian tiger mosquito, could occur in ... Atlanta from June through September, and year-round in Miami. The ...
... with Down syndrome (DS) suffer from marked muscle weakness. Even the ... chair or climbing a flight of stairs, can become major obstacles. ... and lead to a loss of independence. Now, a new study ... Led by scientists from Syracuse University, a research team ...
Cached Biology News:Dust-plumes power intercontinental microbial migrations 2Chances seen rising for chikungunya outbreaks in NYC, Atlanta, Miami 2Study offers insights into role of muscle weakness in Down syndrome 2Study offers insights into role of muscle weakness in Down syndrome 3
Rat Epidermal Keratinocytes (REK) (>500,000 cells)...
Porcine Coronary Artery Endothelial Cells (PCAEC) (>500,000 cells)...
...
Porcine Aortic Smooth Muscle Cells (PAOSMC) (>500,000 cells)...
Biology Products: